NEW YORK (GenomeWeb News) – Siemens and National Jewish Medical and Research Center in Denver will collaborate on developing medical imaging and diagnostic technologies that use genomics, proteomics, and integrated research and clinical care, the partners announced today.
Although the firms did not disclose what kinds of genomics and proteomics technologies they would employ, National Jewish intends to integrate Siemens’ technologies throughout its institution to help diagnose respiratory, cardiac, and rheumatologic diseases. The center’s Institute for Advanced Biomedical Imaging, which is scheduled to open this spring, will house computed tomography and positron emission tomography-CT systems, as well as other imaging systems, made by Siemens.
The Institute will carry out the collaborative research between the partners, they said.
“Integrating new concepts for early detection, including state-of-the-art imaging and information technologies, as well as molecular methods, will help support our shared vision of personalized healthcare,” Heinrich Kolem, CEO of Siemens Medical Solutions USA, said in a statement.
In 2005, Siemens acquired Bayer Diagnostics for approximately $5.25 billion and Diagnostic Products Corp. for nearly $2 billion in a bid to dramatically expand its in vitro diagnostics offerings and provide a complementary portfolio of technologies for its in vivo imaging systems. The firm has said that the combination of Bayer’s molecular diagnostics products with its own molecular imaging technologies is part of its broad “patient-centric” product development strategy.
Siemens’ rivals in the medical imaging field including GE Healthcare and Philips have also become more involved in molecular medicine research through a variety of collaborations.